Table 4 Comparison of previous reports
n | M/F | Diagnosis | Positive | Prevalence | Antibody measure method | |
|---|---|---|---|---|---|---|
Rhoads et al. 2011 [4] | 7 | 3/4 | Schizophrenia | 0 | 0.0 % | Cell-based assay NR1 |
Zandi et al. 2011 [7] | 46 | ns | Early-stage psychiatric disorder | 4 | 6.5 % | Cell-based assay NR1/NR2B |
Schizophrenia 63 % | ||||||
Atypical psychosis 15 % | ||||||
Mood disorder 4 % | ||||||
Bipolar disorder 4 % | ||||||
Major depression 2 % | ||||||
Paranoia 2 % | ||||||
Haussleiter et al. 2012 [5] | 50 | 17/33 | Psychiatric disorder | 0 | 0.0 % | Cell-based assay NR1/NR2B, NR1/NR1 |
Masdeu et al. 2012 [6] | 80 | Schizophrenia | 0 | 0.0 % | Cell-based assay NR1 | |
Tsutsui et al. 2012 [8] | 51 | ns | Schizophrenia | 4 | 7.8 % | Cell-based assay NR1/NR2B |
5 | ns | Narcolepsy with psychiatric symptom | 3 | 60.0 % | ||
Steiner et al. 2013 [9] | 121 | 77/44 | Schizophrenia | 12 | 9.9 % | Cell-based assay NR1/NR2B |
70 | 26/44 | Major depression | 2 | 2.8 % | ||
38 | 14/24 | Borderline personality disorder | 0 | 0.0 % | ||
Hammer et al. 2014 [10] | 1272 | 780/492 | Healthy control | 137 | 10.8 % | Cell-based assay NR1/NR2B |
1081 | 723/358 | Schizophrenia | 93 | 8.6 % | ||
148 | 70/78 | Affective disorder | 24 | 16.2 % | ||
Steiner et al. 2014 [11] | 357 | ns | Healthy control | 25 | 7.0 % | Indirect immunofluorescence BIOCHIP assay (commercial) |
184 | ns | Schizophrenia | 18 | 9.8 % | ||
99 | ns | Major depression | 5 | 5.1 % | ||
42 | ns | Borderline personality disorder | 1 | 2.4 % | ||
Our report 2015 | 59 | 23/36 | Total | 6 | 10.2 % | Cell-based assay NR1/NR2B |
44 | 15/29 | Schizophrenia | 4 | 9.1 % | ||
1 | 1/0 | Major depression | 1 | 100.0 % | ||
4 | 1/3 | Undetermined | 1 | 25.0 % | ||
1 | 1/0 | Nonherpetic limbic encephalitis | 0 | 0.0 % | ||
1 | 0/1 | Atypical psychosis | 0 | 0.0 % | ||
4 | 1/3 | Acute transient psychosis | 0 | 0.0 % | ||
1 | 1/0 | Bipolar disorder | 0 | 0.0 % | ||
2 | 1/1 | Organic psychosis | 0 | 0.0 % | ||
1 | 1/0 | Mental retardation | 0 | 0.0 % |